Study of Autologous Platelet Rich Plasma PRP Injection to Improve Ovarian Function in Women Aged 40 to 50 with Perimenopausal Symptoms

What this Trial Is About

Researchers are evaluating autologous Platelet Rich Plasma PRP intra ovarian infusion to improve ovarian function and hormonal balance in perimenopausal women aged 40 to 50 who experience menstrual cycle irregularities. This triple-blind randomized controlled trial explores PRP, a blood plasma enriched with growth factors, which may stimulate ovarian tissue growth and follicle development. The study aims to clarify PRPs potential role in ovarian rejuvenation, which has been used in other medical fields but remains understudied for reproductive health. Participants are randomly assigned to receive either the autologous PRP intra ovarian infusion or a placebo infusion of autologous Platelet Free Plasma PFP. The treatment involves administering these infusions directly into the ovaries. The study includes follow-up evaluations over three months, with monthly monitoring of menstrual cycle regularity and various hormone levels including FSH, AMH, LH, estradiol, and progesterone, as well as antral follicle count to assess ovarian response. During the study, participants undergo monthly hormonal blood tests and ultrasound scans for antral follicle counting. Researchers will measure restoration of menstrual cycle regularity and hormone profiles as primary outcomes. Secondary outcomes include changes in several hormone levels. The study includes safety monitoring and requires participants to comply with treatment and follow-up schedules. Total duration for participant involvement is about three months of follow-up after the intervention.

Autologous Platelet Rich Plasma (PRP) Intra Ovarian Infusion in Perimenopausal Women